Security National Bank of Sioux City Iowa’s Xilio Therapeutics XLO Stock Holding History

Security National Bank of Sioux City Iowa’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.08K	Buy	+321	New	+$2.68K	﹤0.01%	274

Other funds holding XLO

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Security National Bank of Sioux City Iowa's XLO Position: Q2 2026 in Review

Security National Bank of Sioux City Iowa opened a new position in Xilio Therapeutics (XLO) in Q2 2026: 321 shares worth $3.08K. The stake represents ﹤0.01% of the portfolio and ranks #274 among its holdings.

27 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

Security National Bank of Sioux City Iowa held 321 shares of Xilio Therapeutics worth $3.08K as of Q2 2026.
Xilio Therapeutics was a new Security National Bank of Sioux City Iowa position in Q2 2026.
Xilio Therapeutics made up ﹤0.01% of Security National Bank of Sioux City Iowa's portfolio in Q2 2026, its #274 holding.
27 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Security National Bank of Sioux City Iowa's 13F filing for Q2 2026, filed 18 Sep 2026.